AstraZeneca PLC (AZN) NYSE

177.45

-2.26(-1.26%)

Updated at June 02 04:00PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Pascal Claude Roland Soriot	Chief Executive Officer & Executive Director	8.23M	1959
Aradhana Sarin	Chief Financial Officer & Executive Director	3.65M	1974
Jeffrey Pott	CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board	0	N/A
Pam Cheng	EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board	0	1970
Ruth March	Senior Vice President of Precision Medicine - R&D Oncology	0	N/A
Ruud Dobber	Executive Vice-President of BioPharmaceuticals Business Unit	0	N/A
Joris Silon	Head of Investor Relations	0	N/A
David Fredrickson	Executive Vice-President of Oncology Haematology Business Unit	0	1976
Susan Mary Galbraith	Executive Vice President of Oncology R&D	0	1966
Iskra Reic	Executive Vice President of International	0	N/A

Name

Title

Pay

Year Born

Pascal Claude Roland Soriot

Chief Executive Officer & Executive Director

8.23M

1959

Aradhana Sarin

Chief Financial Officer & Executive Director

3.65M

1974

Jeffrey Pott

CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board

N/A

Pam Cheng

EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board

1970

Ruth March

Senior Vice President of Precision Medicine - R&D Oncology

N/A

Ruud Dobber

Executive Vice-President of BioPharmaceuticals Business Unit

N/A

Joris Silon

Head of Investor Relations

N/A

David Fredrickson

Executive Vice-President of Oncology Haematology Business Unit

1976

Susan Mary Galbraith

Executive Vice President of Oncology R&D

1966

Iskra Reic

Executive Vice President of International

N/A

Description

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.